Neurocognitive and neuroanatomical maturation in the clinical high-risk states for psychosis: A pattern recognition study.


Journal

NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070

Informations de publication

Date de publication:
2019
Historique:
received: 17 07 2018
revised: 14 11 2018
accepted: 01 12 2018
pubmed: 12 12 2018
medline: 18 12 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

Findings from neurodevelopmental studies indicate that adolescents with psychosis spectrum disorders have delayed neurocognitive performance relative to the maturational state of their healthy peers. Using machine learning, we generated a model of neurocognitive age in healthy adults and investigated whether individuals in clinical high risk (CHR) for psychosis showed systematic neurocognitive age deviations that were accompanied by specific structural brain alterations. First, a Support Vector Regression-based age prediction model was trained and cross-validated on the neurocognitive data of 36 healthy controls (HC). This produced Cognitive Age Gap Estimates (CogAGE) that measured each participant's deviation from the normal cognitive maturation as the difference between estimated neurocognitive and chronological age. Second, we employed voxel-based morphometry to explore the neuroanatomical gray and white matter correlates of CogAGE in HC, in CHR individuals with early (CHR-E) and late (CHR-L) high risk states. The age prediction model estimated age in HC subjects with a mean absolute error of ±2.2 years (SD = 3.3; R Although the generalizability of our findings might be limited due to the relatively small number of participants, CHR individuals exhibit a disturbed neurocognitive development as compared to healthy peers, which may be independent of conversion to psychosis and paralleled by an altered structural maturation process.

Sections du résumé

BACKGROUND
Findings from neurodevelopmental studies indicate that adolescents with psychosis spectrum disorders have delayed neurocognitive performance relative to the maturational state of their healthy peers. Using machine learning, we generated a model of neurocognitive age in healthy adults and investigated whether individuals in clinical high risk (CHR) for psychosis showed systematic neurocognitive age deviations that were accompanied by specific structural brain alterations.
METHODS
First, a Support Vector Regression-based age prediction model was trained and cross-validated on the neurocognitive data of 36 healthy controls (HC). This produced Cognitive Age Gap Estimates (CogAGE) that measured each participant's deviation from the normal cognitive maturation as the difference between estimated neurocognitive and chronological age. Second, we employed voxel-based morphometry to explore the neuroanatomical gray and white matter correlates of CogAGE in HC, in CHR individuals with early (CHR-E) and late (CHR-L) high risk states.
RESULTS
The age prediction model estimated age in HC subjects with a mean absolute error of ±2.2 years (SD = 3.3; R
CONCLUSION
Although the generalizability of our findings might be limited due to the relatively small number of participants, CHR individuals exhibit a disturbed neurocognitive development as compared to healthy peers, which may be independent of conversion to psychosis and paralleled by an altered structural maturation process.

Identifiants

pubmed: 30528960
pii: S2213-1582(18)30372-3
doi: 10.1016/j.nicl.2018.101624
pmc: PMC6413470
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101624

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Lana Kambeitz-Ilankovic (L)

Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany. Electronic address: lana.kambeitz-ilankovic@med.uni-muenchen.de.

Shalaila S Haas (SS)

Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany; International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany.

Eva Meisenzahl (E)

Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany; LVR-Klinikum Düsseldorf, Kliniken der Heinrich-Heine-Universität Düsseldorf, Germany.

Dominic B Dwyer (DB)

Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.

Johanna Weiske (J)

Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.

Henning Peters (H)

Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.

Hans-Jürgen Möller (HJ)

Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.

Peter Falkai (P)

Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.

Nikolaos Koutsouleris (N)

Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH